Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Recommendation of “Hold” from Brokerages

Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned a consensus rating of “Hold” from the sixteen ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $88.22.

A number of research firms have commented on GILD. HSBC began coverage on shares of Gilead Sciences in a research report on Wednesday, September 6th. They set a “reduce” rating and a $71.00 price target on the stock. Morgan Stanley boosted their target price on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock an “equal weight” rating in a report on Friday, August 4th. Leerink Partnrs reiterated a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. UBS Group dropped their target price on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a report on Wednesday, November 8th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Gilead Sciences in a report on Thursday, November 9th. They issued a “hold” rating and a $75.00 target price on the stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the chief financial officer now directly owns 104,003 shares of the company’s stock, valued at $8,320,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the chief financial officer now directly owns 104,003 shares of the company’s stock, valued at $8,320,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 1,501 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,399,308.70. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Institutional Trading of Gilead Sciences

Large investors have recently added to or reduced their stakes in the business. WealthPlan Investment Management LLC grew its position in Gilead Sciences by 121.2% in the second quarter. WealthPlan Investment Management LLC now owns 2,070 shares of the biopharmaceutical company’s stock worth $971,000 after acquiring an additional 1,134 shares in the last quarter. American Trust bought a new stake in Gilead Sciences in the first quarter worth approximately $289,000. Venturi Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter worth $36,000. Savant Capital LLC lifted its stake in shares of Gilead Sciences by 1.3% in the second quarter. Savant Capital LLC now owns 26,776 shares of the biopharmaceutical company’s stock worth $2,064,000 after buying an additional 356 shares during the last quarter. Finally, First National Trust Co lifted its stake in shares of Gilead Sciences by 10.2% in the first quarter. First National Trust Co now owns 2,774 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 257 shares during the last quarter. 82.33% of the stock is owned by institutional investors.

Gilead Sciences Trading Up 1.2 %

Gilead Sciences stock opened at $75.45 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.34 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $76.82 and a two-hundred day moving average price of $77.30. The firm has a market capitalization of $94.01 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.00 and a beta of 0.32. Gilead Sciences has a 52-week low of $72.87 and a 52-week high of $89.74.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The company had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $6.81 billion. During the same period in the previous year, the firm earned $1.90 EPS. Gilead Sciences’s revenue was up .1% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences will post 6.76 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 64.38%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.